31 results about "Liver triglyceride" patented technology

The invention relates to the technical field of microorganisms, and discloses complex probiotic and use thereof. The complex probiotic consists of bifidobacterium adolescentis CCFM8630, lactobacillusreuteri CCFM8631, lactobacillus rhamnosus CCFM1044 and lactobacillus casei CCFM711. The effect of relieving metabolic syndrome is significantly better than that of CCFM8630 or CCFM8631 used alone or in combination, especially in the reduction of low-density lipoprotein, total cholesterol and liver triglyceride in serum and glutamic-pyruvic transaminase, glutamic oxalacetic transaminase, alkaline phosphatase, IFN-gamma content in the serum and increase the glutathione and superoxide dismutase content in the liver. The decrease or increase range is improved by 7.91%-837.11% compared with the single or double-bacteria combination formula of the CCFM8630 and the CCFM8631. The four-bacteria combination can achieve the remarkable synergistic interaction.

The invention discloses bifidobacterium longum for relieving insulin resistance and application of the bifidobacterium longum, and belongs to the technical field of microorganisms. The bifidobacterium longum NSP008 disclosed by the invention can be used for inhibiting the increase of the body weight and the body fat of an insulin-resistant mouse on the premise of not influencing the food intake; the glucose tolerance of an insulin-resistant mouse is improved, and meanwhile, the blood sugar, serum insulin and an insulin resistance index of the mouse are reduced; the insulin-resistant mouse liver triglyceride and inflammation level can be adjusted, and liver tissue damage can be relieved; the intestinal flora structure is improved, and the growth of intestinal probiotics is promoted. The bifidobacterium longum NSP008 disclosed by the invention is used for preparing a pharmaceutical composition and fermented food for relieving insulin resistance, and has a very wide application prospect.

The invention discloses a traditional Chinese medicine composition for treating simple obesity, and a preparation method and an application thereof. The traditional Chinese medicine composition is prepared by using 5-30 parts by mass of white atractylodes rhizome, 10-30 parts by mass of fried turtle shell, 10-20 parts by mass of inula flowers, 10-20 parts by mass of curcuma zedoary and 10-20 parts by mass of giant knotweed rhizome as raw materials. Specifically, the preparation method comprises the following steps of weighing all medicines according to the above proportions; smashing the fried turtle shell; adding water 10 times by volume that of the fried turtle shell; decocting for 30 minutes; adding traditional Chinese medicinal materials; adding water and decocting for two times, wherein the volume of added water in each time is 8-10 times that of a total mass of the medicines; and the time for each decoction is 0.5-1 hour; merging extract solutions obtained by the two times of decoction; filtering, concentrating, and drying to obtain a dry extract. Animal experiments show that the composition can significantly reduce body weight, liver weight and fat weight of high-fat obese rats, significantly reduce the contents of liver cholesterol and liver triglyceride in the high-fat obese rats, regulate lipid metabolism and improve liver functions. The medicine effects are related to the fact that the composition can increase bile flow, regulate and increase bile acid subfractions that can promote bile secretion and the lipid metabolism.

The invention discloses an application of interleukin-38 in preparing products for preventing and treating obesity and metabolic syndrome. Furthermore, the metabolic syndrome is diabetes and fatty liver; the dosage of interleukin-38 is 2.5 microgram DNA/g weight, and the effective using form is pcDNA3.1-1L-38-His plasmid; the plasmid is structured by using KpnI and XbaI double digest pc DNA 3.1 (+) and interleukin-38 PCR product, and the recombinant plasmid formed by linking enzyme-digested products of the both is pcDNA3.1-1L-38-His plasmid. The interleukin-38 can effectively delay the fat happening and developing progresses, effectively inhibit the mice weight increase, reduce the cell hypertrophy of adipose tissue, effectively regulate the mice adjusting ability to sugar, inhibit the expression of inflammatory cells, and reduce the generation of the liver triglyceride; the application provides a high-efficient, toxic-free and safe new concept for the prevention and treatment of obesity and metabolic syndrome, and has wide application prospect.

The invention discloses an application of litchi peel polyphenol in preparing a drug or healthcare product for reducing liver cholesterol. A great amount of experiments show that the litchi peel polyphenol from litchi peel can effectively reduce the liver cholesterol, liver triglyceride and liver low density lipoprotein cholesterol, so that the fat accumulation in liver can be effectively reduced, and relevant liver diseases such as non-alcoholic fatty liver can be treated.

The invention discloses an application of formononetin to treatment of nonalcoholic fatty liver disease. An in vitro and an in vitro cell model are adopted, formononetin is used for treating animals,and the improvement effect of the formononetin on metabolic syndromes of nonalcoholic fatty liver, obesity, insulin resistance, lipid disorders and the like can be observed. Experiment proves that theformononetin can notably reduce weight, liver weight/body mass indexes, liver triglyceride(TG), liver lipidoses, liver function damage criterion-millet straw aminopherase (AST) and alanine aminotransferase (ALT) of organisms suffering from nonalcoholic fatty liver, and besides, can improve insulin resistance. Blood biochemistry detection indicates that the formononetin can also reduce the level of triglyceride (TG), cholesterol (TC) and low intensity lipoprotein (LDL-C) of HFD mice, and can improve the lipid disorders. The formononetin has important effects on treatment of nonalcoholic fattyliver.

The invention discloses application of betulinic acid as a leptin sensitizer in preparation of related drugs for treating leptin resistance. According to the invention, high-fat, ob/ob and db/db obesemice are taken as research objects and treated with the betulinic acid, and the weight, serum leptin concentration, liver triglyceride, insulin tolerance and glucose tolerance tests and blood fat indexes are measured. The results show that the betulinic acid can significantly reduce the weight, improve the leptin resistance, lower the liver triglyceride, improve the insulin resistance and lower the blood fat in the high-fat obese mice, the ob/ob and db/db mice treated with the betulinic acid can not reduce the weight and improve the metabolism of glycolipid, and the cellular level proves thatthe combination of the betulinic acid and the leptin can enhance the expression of p-STAT3. The invention provides a basis for treating obesity, a non-alcoholic fatty liver disease, type 2 diabetes and hyperlipidemia by using the betulinic acid as the leptin sensitizer, and also provides a new treatment direction for developing more natural active pharmaceutical ingredients for treating diseasesrelated to the leptin resistance.

The invention belongs to the field of pharmaceutical biology. The estrogen plays an important role in the liver glucolipid metabolism process, has a protection effect to livers and can be used for preparing medicines for treating fatty liver and particularly non-alcoholic fatty liver diseases. A receptor regulated by the estrogen is an SHP (Small Heterodimer Partner) gene, and by adjusting the expression of the liver SHP gene, the synthesis of liver triglyceride and fatty acid is inhibited, and the function of alleviating the fatty liver is brought into play. According to the invention, a specific target is provided for screening a medicine for treating fatty liver, the regulation effect of the estrogen to SHP gene is confirmed, and the relevant relationship between the regulation effect and the NAFLD (Non-Alcoholic Fatty Liver Disease) provides reliable basis and indexes for researching the prevention and treating target points of the fatty liver; and furthermore, from the aspect of endocrine regulation, a new way is provided for preventing and treating glycolipid metabolic diseases.